DMARDs (Disease-Modifying Antirheumatic Drugs) are a group of medicines that slow down or stop the progression of inflammatory arthritis and protect joints from permanent damage.
DMARDs are disease-modifying antirheumatic drugs:immunomodulatory agents used to suppress inflammatory rheumatic disease activity and, importantly, reduce structural damage and disability—not merely relieve pain.
Disease-modifying antirheumatic drugs (DMARDs) are the cornerstone of pharmacologic treatment for inflammatory arthritides such as rheumatoid arthritis (RA), psoriatic arthritis, and axial spondyloarthritis.
They are foundational in rheumatoid arthritis (RA), and are also used across psoriatic arthritis, spondyloarthritis, SLE, vasculitis, inflammatory myopathies, and selected inflammatory bowel/uveitic disorders.
They can calm down an overactive immune system that attacks healthy joint tissue.
Unlike pain relievers (NSAIDs) or steroids that only hide symptoms, DMARDs target the underlying disease to prevent long-term joint destruction.
They take weeks or months to reach full effectiveness.
Main Types of DMARDs
Conventional Synthetic csDMARDs: Traditional chemical medications that broadly affect the immune system. Methotrexate, Hydroxychloroquine, Sulfasalazine, Leflunomide
Biologic DMARDs: Lab-made proteins targeting specific parts of the immune system.
They often work faster than conventional options. Adalimumab, Etanercept, Infliximab
They suppress the immune system, and raise the risk of acquiring serious infections.
Taking live vaccines is dangerous while on these medications.
Certain DMARDs can harm a developing fetus.
Unlike NSAIDs or analgesics — which relieve pain and stiffness but do not alter disease course — DMARDs suppress the underlying immune-mediated inflammation, thereby reducing symptoms and, critically, preventing or slowing irreversible joint damage.
Early initiation (ideally within ~3 months of onset) using a treat-to-target strategy improves long-term outcomes.
Three classes are recognized, categorized by structure and mechanism:
Conventional synthetic DMARDs (csDMARDs): small synthetic molecules with broad, largely non-specific immunomodulatory effects. Includes methotrexate (the anchor/first-line drug), hydroxychloroquine, sulfasalazine, and leflunomide; less commonly azathioprine, cyclosporine, and gold.
Methotrexate acts on folate-dependent enzymes with cell-type-specific effects.
Methotrexate is first-line for RA and the backbone of most combination regimens unless contraindicated; combination of a b/tsDMARD plus csDMARD is often more effective than monotherapy.
Biologic DMARDs (bDMARDs): biologically derived proteins are mostly monoclonal antibodies or receptor constructs, targeting specific cytokines or cells.
Categories include:
TNF inhibitors — adalimumab, etanercept, infliximab, golimumab, certolizumab pegol
Protein-based targeted therapies, generally injectable or infused
IL-17 inhibitors (secukinumab, ixekizumab) and IL-23/IL-12-23 inhibitors (guselkumab, ustekinumab) — used in psoriatic arthritis and spondyloarthritis
bDMARDs are further divided into bio-originator and biosimilar products
Targeted synthetic DMARDs (tsDMARDs): small molecules designed against a specific intracellular target, principally JAK inhibitors (tofacitinib, baricitinib).
Targeted synthetic DMARDs (tsDMARDs) | JAK inhibitors: tofacitinib, baricitinib, upadacitinib; filgotinib where available | Oral small molecules targeting intracellular cytokine signaling
IL-6 inhibitors — tocilizumab, sarilumab
IL-1 inhibitor — anakinra
T-cell costimulation blocker — abatacept
B-cell depletion — rituximab
Infection risk is the most common shared adverse effect, particularly with bDMARDs and tsDMARDs; screening (e.g., TB, hepatitis) and vaccination are important before initiation.
Perioperative management: csDMARDs such as methotrexate and hydroxychloroquine may generally be continued, whereas b/tsDMARDs are typically withheld before surgery and resumed ~14 days postoperatively once wound healing is established.
Pyrimidine synthesis inhibition Leflunomide-
Hepatotoxicity, teratogenicity, long half-life; cholestyramine washout if needed .
Antimalarial immunomodulator Hydroxychloroquine Retinal toxicity is dose- and duration-related; baseline and ongoing ophthalmic screening
Sulfa-based immunomodulator Sulfasalazine GI intolerance, cytopenias, rash; caution with sulfa allergy depending on reaction history |
TNF-\(\alpha\) blockade Adalimumab, etanercept, infliximab, certolizumab, golimumab Screen for latent TB and hepatitis B; avoid/use extreme caution in significant heart failure or demyelinating disease
T-cell costimulation modulation Abatacept | CTLA-4–Ig; often useful when infection risk or pulmonary considerations influence biologic selection
IL-6 receptor blockade-Tocilizumab, sarilumab Neutropenia, transaminitis, hyperlipidemia; CRP may be pharmacologically suppressed
B-cell depletion-Rituximab
Infusion reactions, HBV reactivation, hypogammaglobulinemia; especially relevant in selected RA, vasculitis, and certain connective-tissue disease contexts
JAK inhibition-Tofacitinib, baricitinib, upadacitinib
Herpes zoster, cytopenias, lipids, thrombosis/MACE and malignancy risk considerations; careful risk stratification is essential.
Hydroxychloroquine, sulfasalazine, methotrexate, and leflunomide as csDMARDs; TNF inhibitors, abatacept, IL-6 inhibitors, and rituximab as biologics; and JAK inhibitors as tsDMARDs.
For newly diagnosed RA, treatment should begin promptly with a DMARD and use a targeted strategy—serial disease-activity measurement with therapy adjusted toward remission or, if that is not attainable, low disease activity. EULAR emphasizes initiating DMARD therapy as soon as RA is diagnosed and targeting sustained remission.
Methotrexate is typically first-line for moderate-to-high activity RA, barring contraindication or intolerance.
If response is inadequate after an adequate dose/duration and adherence assessment, escalation commonly means adding or switching to a bDMARD or tsDMARD, usually with methotrexate where feasible.
Hydroxychloroquine is often reasonable initial monotherapy in lower-activity disease because of tolerability; sulfasalazine is another conventional option.
Glucocorticoids may serve as brief bridge therapy, but prolonged use is generally avoided because of cumulative toxicity.
NSAIDs improve pain and stiffness but do not prevent erosions or modify disease progression; DMARDs do.
Before a biologic or JAK inhibitor, typical pre-treatment workup includes:
TB screening, especially before TNF inhibitors and other advanced immunosuppressants.
Hepatitis B testing, with antiviral prophylaxis/monitoring based on serology and the planned agent—particularly important with rituximab.
CBC, liver enzymes, renal function as appropriate; lipid panel for JAK inhibitors and IL-6 blockade.
Vaccination review: administer indicated non-live vaccines ideally before immunosuppression; live vaccines generally require timing around treatment rather than administration during significant immunosuppression.
Reproductive counseling: methotrexate and leflunomide are contraindicated in pregnancy; agent-specific guidance is required.
Monitoring is drug-specific but commonly includes CBC and transaminases for methotrexate, leflunomide, and sulfasalazine; ophthalmic surveillance for hydroxychloroquine; and infection, cytopenia, hepatic, lipid, and vaccination monitoring for advanced therapies.